News
Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...
The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...
Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...
Losing British drug giant AstraZeneca from the London Stock Exchange would be a “devastating blow”, Tory former chancellor ...
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...
Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.
The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results